Human malignant gliomas represent the most common aggressive malignant brain tumors in adults.  They rank amongst the most deadly cancers affecting humans. Malignant glial tumor cells display marked resistance to treatment, whether by radiotherapy, chemotherapy, or a combination of both. Therefore, the prognosis of these patients remains dismal, with a median survival of 9 to 15 months. Based on our preliminary results, we hypothesize that that the three-dimensional nuclear-organization of telomeres, the ends of chromosomes, is a biomarker that can predict the survival and patient outcome. Therefore, 3D telomere signatures could be a new prognostic, predictive, and potentially pharmacodynamic biomarker in glioblastomas.